Low-Energy Femoral Fractures Associated With Long-Term Bisphosphonate Use in a Rehabilitation Setting: A Case Series

PM and R

Volumn 2, Issue 1, 2010, Pages 76-80

  Bunning, Robert D ^a   Rentfro, Robert J ^a   Jelinek, James S ^a  

^a NATIONAL REHABILITATION HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; VITAMIN D; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE BIOPSY; BONE RADIOGRAPHY; CASE REPORT; DRUG USE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR FRACTURE; HUMAN; MALE; OSTEOPENIA; OSTEOPOROSIS; PHYSIOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; REHABILITATION CARE;

DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 74949124186     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2009.11.007     Document Type: Article

References (12)

1. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment, (Flex): A randomized trial. JAMA 296 (2006) 2927-2938
2. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
3. Ovinda C.V., Zerwekh J.E., Rao S., et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294-1301
4. Lenart B.A., Lorich D.G., and Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358 (2008) 1304-1306
5. Goh S.K., Yang K.Y., Koh J.S.B., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 89 (2007) 349-353
6. Neviaser A.S., Lane J.M., Lenart B.A., Edobor-Osula F., and Lorich D.G. Low energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22 (2008) 346-350
7. Ing-Lorenzini K., Desmeules J., Plachta O., et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates. Drug Safety 32 (2009) 775-785
8. Reina A.V., Panwar V., and Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355 (2006) 2048-2050
9. Kwek E.B., Goh S.K., Koh J.S., Png M.A., and Howe T.S. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy. Injury 39 (2008) 224-231
10. Lenart B.A., Lorich D.G., and Lane J.M. More on atypical fractures of the femoral diaphysis. N Engl J Med 359 (2008) 317-318
11. Wernecke G., Namduri S., DiCarlo E.F., et al. Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSSJ 4 (2008) 123-127
12. Bonnick S., Saag K.G., Kiel D.P., et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91 (2006) 2631-2637